Skip to main content
Signal8

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

$GILDPress releaseMay 22, 2026, 7:47 AM ETRead the release

The European Medicines Agency's CHMP has adopted a positive opinion for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer in patients ineligible for PD-(L)1 inhibitors. This recommendation is based on the Phase 3 ASCENT-03 study, which showed a 38% reduction in the risk of disease progression or death compared to standard chemotherapy. Gilead has also submitted a corresponding application to the U.S. FDA for this indication, with a decision anticipated later in 2026.

Key figures

Drug Name
Trodelvy (sacituzumab govitecan-hziy)
Phase Of Trial
Phase 3
Patients treated
75000
Countries approved
60
Risk reduction pct
38

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    GILD: Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors — AI Analysis | Signal8